Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug 16:4:43.
doi: 10.1186/s40425-016-0147-8. eCollection 2016.

It's TIME for a biomarker-driven approach to cancer immunotherapy

Leisha A Emens  1
Affiliations

It's TIME for a biomarker-driven approach to cancer immunotherapy

Leisha A Emens. J Immunother Cancer. .
No abstract available

PubMed Disclaimer

References

    1. Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL. Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol. 2015;42:587–600. doi: 10.1053/j.seminoncol.2015.05.013. - DOI - PMC - PubMed
    1. Emens LA, Jaffee EM. Cancer vaccines: on the threshold of success. Cancer Biol Ther. 2003;2(Suppl1):S161–S168. doi: 10.4161/cbt.2.2.283. - DOI - PubMed
    1. Emens LA. Roadmap to a better therapeutic tumor vaccine. Intl Rev Immunol. 2006;25:415–443. doi: 10.1080/08830180600992423. - DOI - PubMed
    1. Emens LA, Silversten SC, Khleif S, Marincola FM, Galon J. Toward integrative cancer immunotherapy: targeting the tumor microenvironment. J Transl Med. 2012;10:70. doi: 10.1186/1479-5876-10-70. - DOI - PMC - PubMed
    1. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Pensen DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–422. doi: 10.1056/NEJMoa1001294. - DOI - PubMed

LinkOut - more resources